A Long-term Study to Evaluate the Efficacy and Safety of AK102 in Combination With Lipid-lowering Therapy in Patients With Hypercholesterolemia
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Ebronucimab (Primary) ; Ezetimibe; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Akeso Biopharma
Most Recent Events
- 01 Mar 2023 Status changed to completed.
- 25 Nov 2019 New trial record